대장암(CRC) 검진 시장 : 규모, 점유율, 성장, 업계 분석, 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of colorectal cancer (CRC) screening Market

The global colorectal cancer (CRC) screening market was valued at USD 18.62 billion in 2025 and is projected to grow to USD 19.42 billion in 2026, reaching USD 27.69 billion by 2034, exhibiting a CAGR of 4.50% during the forecast period. North America dominated the market in 2025 with a 65.04% share, driven by high awareness, early detection programs, and favorable reimbursement policies. CRC primarily affects adults aged 45 and above, with early detection significantly improving treatment outcomes. The rising prevalence of colorectal cancer and government initiatives promoting screening are key drivers fueling market growth.

Market Drivers

The increasing incidence of colorectal cancer is a major market driver. Developed countries report higher incidence rates, while middle- and low-income countries are witnessing rising cases due to unhealthy lifestyles and aging populations. According to the American Cancer Society in 2025, rectal cancer and colon cancer cases in the U.S. were 46,950 and 107,320, respectively. Furthermore, the Centers for Disease Control and Prevention (CDC) reported 147,931 new colorectal cancer cases in the U.S. in 2022, with 53,779 deaths in 2023. This rising incidence and mortality have heightened the demand for CRC detection and are expected to propel market growth.

Market Restraints

Despite strong clinical rationale, the market faces significant restraints. Low screening participation, especially in low- and middle-income countries, limits adoption. Even in developed regions, fear, discomfort, and lack of awareness reduce screening uptake. Colonoscopy, the gold standard, is invasive, requires bowel preparation, sedation, and specialized infrastructure, driving up per-test costs. Emerging modalities like stool-DNA and blood-based tests are expensive compared to fecal immunochemical tests (FIT), restricting access and limiting public program inclusion. Reimbursement variability also contributes to uneven access globally.

Market Opportunities

Non-invasive and at-home CRC screening tests are emerging as substantial opportunities. These tests, such as FIT, fecal occult blood tests (FOBT), and multi-target stool DNA tests, eliminate procedural risks, bowel preparation, and discomfort, enhancing adoption among asymptomatic and screening-averse populations. In July 2024, Guardant Health received FDA approval for its Shield blood test as the first primary screening option for adults aged 45 and above, supporting Medicare reimbursement. Collaborations among diagnostics companies, healthcare providers, and public health agencies are enabling home testing and digital reporting, further increasing compliance and repeat testing rates.

Market Challenges

Colonoscopy, while accurate, carries procedural risks such as perforation, bleeding, infection, and sedation-related complications, limiting its uptake. A 2025 study published by NCBI indicated perforation and bleeding rates of 0.078% and 0.235%, respectively, among adults over 65, with higher risks in those over 80. Awareness of these risks is shifting preference toward non-invasive stool-based and molecular tests, restricting colonoscopy adoption.

Market Trends

The market is witnessing a shift toward less invasive, patient-friendly pathways. Stool-based tests are increasingly used as first-line screening, reserving colonoscopy for confirmation. Technological advancements in colonoscopy, such as high-definition imaging, AI-based polyp detection, and single-use endoscopes, are improving diagnostic yield while addressing infection risks.

Segmentation Analysis

By Type:

• Colonoscopy dominated the market in 2026 with 71.27% share due to its high accuracy.
• Stool-based tests are projected to grow at a CAGR of 10.7%, including FIT, gFOBT, and stool-DNA tests.

By End-User:

• Hospitals & clinics held 53.04% of the global market in 2026, driven by high patient volumes.
• Clinical laboratories are expected to grow at a CAGR of 6.4% during the forecast period.

Regional Outlook

• North America: Dominated the market in 2025 (USD 12.11 billion) and 2026 (USD 12.64 billion), with the U.S. accounting for USD 12.44 billion in 2026 (64% of global revenues).
• Europe: Projected to grow at CAGR 8.3%, valued at USD 0.90 billion in 2025. Key markets include the U.K. (USD 0.17 billion in 2026) and Germany (USD 0.40 billion in 2026).
• Asia Pacific: Estimated at USD 4.86 billion in 2025, with Japan at USD 0.57 billion (2026) and China at USD 1.96 billion (2026). India contributes USD 1.71 billion (2026).
• Latin America & Middle East & Africa: Emerging markets, including Saudi Arabia (USD 0.10 billion in 2025), are expanding due to awareness programs and increased availability of screening tests.

Competitive Landscape

Prominent players include Olympus Corporation, Exact Sciences Corporation, Quest Diagnostics, FUJIFILM Holdings, and Clinical Genomics Technologies, focusing on advanced colonoscopy and stool-based products. Recent developments include:

• January 2025: NHS England rollout of home FIT screening.
• August 2024: Guardant Health Shield blood test FDA-approved and Medicare-covered.
• February 2024: Launch of ColoTest by Reese Pharmaceutical.
• November 2023: Shield blood-based CRC test launched in South Korea.

Conclusion

The global colorectal cancer screening market is poised for steady growth, fueled by rising CRC incidence, technological innovations, and adoption of non-invasive and home-based screening tests. While colonoscopy remains the gold standard, non-invasive solutions are expanding access, improving compliance, and driving market expansion globally. By 2034, the market is expected to reach USD 27.69 billion, offering significant opportunities for diagnostic companies, healthcare providers, and public health agencies worldwide.

Segmentation By Type, End-user, and Region

By Type * Stool-based

• Fecal Immunochemical Test (FIT)
• Fecal Occult Blood Test (FOBT)
• Stool-DNA Test
• Colonoscopy
• Others

By End-user

Hospitals & Clinics

• Clinical Laboratories
• Diagnostic Imaging Centers
• Others

By Region * North America (By Type, End-user, and Country)

• U.S.
• Canada
• Europe (By Type, End-user, and Country/Sub-region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, End-user, and Country/Sub-region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, End-user, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, End-user, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Incidence of Colorectal Cancer (2020) - For Key Countries, 2025
• 4.2. Overview : Colorectal Cancer Screening Programs (Key Countries/ Regions)
• 4.3. New Product Approvals
• 4.4. Overview: Public Private Partnerships, Strategies Implemented by Organizations for Colorectal Cancer Screening - Key Countries
• 4.5. Number of Colorectal Cancer Screening Procedures - For Key Countries, 2025
• 4.6. Average Prices of the Tests in the Market
• 4.7. Key Industry Developments (Mergers, Acquisitions, Partnerships)
• 4.8. Overview : Countries with Overburden of Colonoscopies

5. Global Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Stool-based
    • 5.1.1.1. Fecal Immunochemical Test (FIT)
    • 5.1.1.2. Fecal Occult Blood Test (FOBT)
    • 5.1.1.3. Stool-DNA Test
  • 5.1.2. Colonoscopy
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By End-user
  • 5.2.1. Hospitals & Clinics
  • 5.2.2. Clinical Laboratories
  • 5.2.3. Diagnostic Imaging Centers
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Latin America
  • 5.3.5. Middle East & Africa

6. North America Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Stool-based
    • 6.1.1.1. Fecal Immunochemical Test (FIT)
    • 6.1.1.2. Fecal Occult Blood Test (FOBT)
    • 6.1.1.3. Stool-DNA Test
  • 6.1.2. Colonoscopy
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By End-user
  • 6.2.1. Hospitals & Clinics
  • 6.2.2. Clinical Laboratories
  • 6.2.3. Diagnostic Imaging Centers
  • 6.2.4. Others
• 6.3. Market Analysis - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Stool-based
    • 7.1.1.1. Fecal Immunochemical Test (FIT)
    • 7.1.1.2. Fecal Occult Blood Test (FOBT)
    • 7.1.1.3. Stool-DNA Test
  • 7.1.2. Colonoscopy
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By End-user
  • 7.2.1. Hospitals & Clinics
  • 7.2.2. Clinical Laboratories
  • 7.2.3. Diagnostic Imaging Centers
  • 7.2.4. Others
• 7.3. Market Analysis - By Country/Sub-region
  • 7.3.1. U.K.
  • 7.3.2. Germany
  • 7.3.3. France
  • 7.3.4. Spain
  • 7.3.5. Italy
  • 7.3.6. Scandinavia
  • 7.3.7. Rest of Europe

8. Asia pacific Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Stool-based
    • 8.1.1.1. Fecal Immunochemical Test (FIT)
    • 8.1.1.2. Fecal Occult Blood Test (FOBT)
    • 8.1.1.3. Stool-DNA Test
  • 8.1.2. Colonoscopy
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By End-user
  • 8.2.1. Hospitals & Clinics
  • 8.2.2. Clinical Laboratories
  • 8.2.3. Diagnostic Imaging Centers
  • 8.2.4. Others
• 8.3. Market Analysis - By Country/Sub-region
  • 8.3.1. China
  • 8.3.2. India
  • 8.3.3. Japan
  • 8.3.4. Australia
  • 8.3.5. Southeast Asia
  • 8.3.6. Rest of Asia Pacific

9. Latin America Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Stool-based
    • 9.1.1.1. Fecal Immunochemical Test (FIT)
    • 9.1.1.2. Fecal Occult Blood Test (FOBT)
    • 9.1.1.3. Stool-DNA Test
  • 9.1.2. Colonoscopy
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By End-user
  • 9.2.1. Hospitals & Clinics
  • 9.2.2. Clinical Laboratories
  • 9.2.3. Diagnostic Imaging Centers
  • 9.2.4. Others
• 9.3. Market Analysis - By Country/Sub-region
  • 9.3.1. Brazil
  • 9.3.2. Mexico
  • 9.3.3. Rest of Latin America

10. Middle East & Africa Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Stool-based
    • 10.1.1.1. Fecal Immunochemical Test (FIT)
    • 10.1.1.2. Fecal Occult Blood Test (FOBT)
    • 10.1.1.3. Stool-DNA Test
  • 10.1.2. Colonoscopy
  • 10.1.3. Others
• 10.2. Market Analysis, Insights and Forecast - By End-user
  • 10.2.1. Hospitals & Clinics
  • 10.2.2. Clinical Laboratories
  • 10.2.3. Diagnostic Imaging Centers
  • 10.2.4. Others
• 10.3. Market Analysis - By Country/Sub-region
  • 10.3.1. GCC
  • 10.3.2. South Africa
  • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Company Share Analysis for Stool-based Tests, 2025
• 11.2. Company Share Analysis for Colonoscopes, 2025
• 11.3. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
  • 11.3.1. NOVIGENIX SA
  • 11.3.2. EIKEN CHEMICAL CO., LTD.
  • 11.3.3. Clinical Genomics Technologies Pty Ltd.
  • 11.3.4. Exact Sciences Corporation
  • 11.3.5. Epigenomics AG
  • 11.3.6. bioMerieux, Inc.
  • 11.3.7. OLYMPUS CORPORATION
  • 11.3.8. KARL STORZ SE & Co. KG
  • 11.3.9. FUJIFILM Holdings America Corporation